Verrucous Psoriasis: Rare Variant and Novel Treatment
180401804018040
JDD authors Dimitra Xenopoulou MS, Christopher Pochat MS, and Evelyn Greco DO present the findings of a successful treatment for verrucous psoriasis.
CASE
A 64-year-old female presented to the outpatient clinic for the evaluation of flaking and itchy lesions on her bilateral hands and feet that were present for several months and caused difficulty with activities of daily living. Inconsist …
JDD authors Dimitra Xenopoulou MS, Christopher Pochat MS, and Evelyn Greco DO present the findings of a successful treatment for verrucous psoriasis.
CASE
A 64-year-old female presented to the outpatient clinic for the evaluation of flaking and itchy lesions on her bilateral hands and feet that were present for several months and caused difficulty with activities of daily living. Inconsist … Continue reading "Verrucous Psoriasis: Rare Variant and Novel Treatment"
Roflumilast is a non-steroidal topical cream that was FDA approved for the treatment of plaque psoriasis in 2022.1 Roflumilast selectively inhibits phosphodiesterase-4 (PDE-4), which is an enzyme that mediates inflammatory responses and has been shown to play a role in several dermatologic diseases.2 Prior to topical roflumilast, oral PDE-4 inhibitors have been investigated across a wide variety o … 
Apremilast (OTEZLA®) is a twice daily oral medication that is FDA approved for adults with plaque psoriasis, psoriatic arthritis and oral ulcers associated with Behçet’s Disease.1 This drug is being extended as an off-label treatment to target inflammation in a number of different conditions. This Therapeutic Cheat Sheet will focus on apremilast and its applications for different dermatologica … 
Before we dive into our discussion, let’s outline the Guideline-Based Approach to Treatment Selection.
The International Psoriasis Council has divided psoriasis treatment classification into 2 groups:
Patients who are a candidate for topical therapy, or
Patients who are a candidate for systemic therapy
Candidates for systemic therapy must meet at least 1 of the following … 
Palmoplantar pustulosis (PPP) is a rare, recurrent skin disorder that presents a major challenge to clinical therapy. JDD author Danilo C. Del Campo, MD, FAAD reports a case of a 69-year-old woman with a 20-year history of psoriasis with skin manifestations and clinical and pathologic features consistent with PPP. After intolerance to apremilast and unsuccessful use of topical corticosteroids and … 